Traders Are Watching: Cleveland BioLabs, Inc. (NASDAQ:CBLI), Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), pSivida Corp. (NASDAQ:PSDV), Atlanticus Holdings Corporation (NASDAQ:ATLC), Primoris Services Corporation (NASDAQ:PRIM)

Cleveland BioLabs, Inc. (NASDAQ:CBLI) belongs to Healthcare sector. Its net profit margin is -13.30% and weekly performance is -3.08%. On last trading day company shares ended up $3.78. Cleveland BioLabs, Inc. (NASDAQ:CBLI) distance from 50-day simple moving average (SMA50) is 28.29%. Cleveland BioLabs, Inc. (NASDAQ:CBLI) announced the results of a Phase 1 single-blinded, randomized, placebo-controlled, healthy-subject study of CBLB612, an investigational drug in development for oncology indications, including the prevention of chemotherapy-induced myelosuppression.

Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) shares moved down -2.99% in last trading session and ended the day at $2.27. OHRP return on assets is -35.60%. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) quarterly performance is -18.93%. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) announced positive final results from a Phase II investigator sponsored clinical trial of OHR-102 in patients with macular edema secondary to branch or BRVO and central retinal vein occlusion or CRVO.

On 10 July, pSivida Corp. (NASDAQ:PSDV) shares advanced 4.08% and was closed at $4.08. PSDV EPS growth in last 5 year was -28.50%. pSivida Corp. (NASDAQ:PSDV) year to date (YTD) performance is -0.73%. pSivida Corp. (NASDAQ:PSDV) announced positive top line results from a Phase II investigator-sponsored study of pSivida’s Medidur for uveitis affecting the posterior of the eye (posterior, intermediate and pan-uveitis). Dr. Glenn J. Jaffe, Robert Machemer Professor of Ophthalmology at Duke University School of Medicine in Durham, NC, presented the top line results during an oral abstract session at the American Society of Retina Specialists in Vienna, Austria, reporting a statistically significant reduction in recurrence of uveitis and a statistically significant improvement in visual acuity in eyes treated with Medidur.

Atlanticus Holdings Corporation (NASDAQ:ATLC) ended the last trading day at $4.01. Company weekly volatility is calculated as 8.75% and price to cash ratio as 1.96. Atlanticus Holdings Corporation (NASDAQ:ATLC) showed a weekly performance of 6.37%.

Primoris Services Corporation (NASDAQ:PRIM) shares advanced 0.42% in last trading session and ended the day at $19.04. PRIM Gross Margin is 11.20% and its return on assets is 4.90%. Primoris Services Corporation (NASDAQ:PRIM) quarterly performance is 3.99%. Primoris Services Corporation (NASDAQ:PRIM) announced that its Board of Directors has approved an executive transition effective August 1, 2015. Brian Pratt will step down from his position as Chief Executive Officer and President, while remaining as Chairman of the Board and assuming the non-employee role of Senior Strategic Advisor. David King, the Company’s current Chief Operating Officer, will become the new Chief Executive Officer and President.

Leave a Reply

Your email address will not be published. Required fields are marked *